-
341
-
342
Analysis of the Influence of microRNAs in Lithium Response in Bipolar Disorder
Published 2018-05-01Get full text
Article -
343
Promoting RAPID Vaccine Science Education at the Onset of the COVID-19 Pandemic
Published 2023-08-01Get full text
Article -
344
-
345
Response to Placebo in Fragile X Syndrome Clinical Trials: An Initial Analysis
Published 2020-09-01Get full text
Article -
346
-
347
Identification and Morphogenesis of Vestibular Atrial Septal Defects
Published 2020-09-01Get full text
Article -
348
-
349
-
350
-
351
-
352
-
353
Phase 3 Efficacy (Worse-Eye Analysis) and Long-Term Safety Evaluation of OTX-101 in Patients with Keratoconjunctivitis Sicca
Published 2021-01-01“…John Sheppard,1 Mark Bergmann,2 Barry A Schechter,3 Jodi Luchs,4 Abayomi Ogundele,5 Paul Karpecki6 1Virginia Eye Consultants, Norfolk, VA, USA; 2Apex Eye, Cincinnati, OH, USA; 3Florida Eye Microsurgical Institute, Boynton Beach, FL, USA; 4Florida Vision Institute, West Palm Beach, FL, USA; 5Medical Affairs, Sun Pharmaceutical Industries, Inc, Princeton, NJ, USA; 6Kentucky Eye Institute, Lexington, KY, USACorrespondence: John SheppardVirginia Eye Consultants, Suite #210, 241 Corporate Blvd, Norfolk, VA 23502, USATel +1 757 226-8021Email jsheppard@cvphealth.comBackground: OTX-101 is approved for treatment of keratoconjunctivitis sicca (KCS). …”
Get full text
Article -
354
-
355
Diagnosis and Treatment of Urticaria and Angioedema: A Worldwide Perspective
Published 2012-01-01Get full text
Article -
356
Multi-site observational maternal and infant COVID-19 vaccine study (MOMI-vax): a study protocol
Published 2022-05-01Get full text
Article -
357
-
358
-
359
-
360
GA4GH: International policies and standards for data sharing across genomic research and healthcare
Published 2021-11-01Get full text
Article